Orsted stock rating upgraded by Morgan Stanley on renewables cycle shift

Orsted A/S is facing sharply divergent analyst sentiment, with Morgan Stanley upgrading the renewable energy firm to Overweight, raising its price target to DKK360.00, citing an expected turning point in the renewables cycle, favorable U.S. tax credit outcomes, and reduced project cancellation risks. Conversely, Citi downgraded Orsted to Sell, significantly lowering its price target to DKK211.00, due to concerns over its balance sheet, U.S. project funding strategy, and a premium valuation relative to peers amidst an uncertain U.S. outlook, creating a highly contested investment case for the European utility.

Analysis

Orsted A/S presents a highly contested investment case, underscored by sharply divergent analyst ratings from Morgan Stanley and Citi. Morgan Stanley upgraded the stock to Overweight with a DKK360 price target, anticipating a cyclical recovery in renewables and citing positive U.S. regulatory developments, such as favorable IRA tax credit outcomes, which reduce the cancellation risk for its Sunrise and Revolution offshore wind projects. Conversely, Citi downgraded the stock to Sell, slashing its price target to DKK211 due to significant concerns over balance sheet health, the strategy of funding U.S. projects by selling operating cash flows, and potential execution risks including cost overruns and tariff impacts. The valuation picture is equally polarized; while the company maintains strong liquidity with a current ratio of 1.24, it trades at a high P/E of 103.7x and a price-to-book of 1.1x, a premium to the peer average of 0.7-0.8x that Citi finds unjustified given the U.S. uncertainty. Morgan Stanley acknowledges near-term headwinds, forecasting the upcoming August 13 quarterly results to be "the last messy quarter" due to one-off charges from the Hornsea 4 project cancellation.

Key Decisions for Investors

• Investors should recognize the pronounced analyst divergence on Orsted, which signals a period of heightened risk and potential volatility contingent on the successful execution of its U.S. project pipeline.
• The upcoming August 13 quarterly results are a critical catalyst; focus should be on management's guidance regarding U.S. project funding, cost controls, and the financial impact of the Hornsea 4 cancellation to validate either the bullish or bearish thesis.
• Given the stock's premium price-to-book valuation relative to peers and its high P/E ratio, potential investors should carefully weigh the growth prospects outlined by Morgan Stanley against the significant execution risks and balance sheet concerns highlighted by Citi before establishing a position.